We are live on !
Find out more
Jim Simons Renaissance Technologies
AUM
$72.6B
Turnover
31.08%
1-Year Est. Return
54.88%
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+54.88%
3 Year Est. Return
+169.34%
5 Year Est. Return
+186.18%
10 Year Est. Return
+887.92%
AUM
$118B
AUM Growth
+$4.56B
(+4%)
Cap. Flow
+$5.29B
Cap. Flow % of AUM
Cap. Flow %
4.48%
Top 10 Holdings %
Top 10 Hldgs %
10.69%
Holding
3,920
New
407
Increased
1,847
Reduced
1,112
Closed
522
Avg Time Held
2.5
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$628M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$567M |
| 3 |
Biogen
BIIB
|
+$405M |
| 4 |
UnitedHealth
UNH
|
+$392M |
| 5 |
Walmart Inc
WMT
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$451M |
| 2 |
PepsiCo
PEP
|
+$382M |
| 3 |
Philip Morris
PM
|
+$256M |
| 4 |
Roku
ROKU
|
+$252M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.34% |
| 2 | Technology | 12.68% |
| 3 | Consumer Discretionary | 10.36% |
| 4 | Financials | 10.32% |
| 5 | Consumer Staples | 8.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$128B
| $1.66B | 1.41% |
32,757,770
+12,059,163
| +58% | +$567M |
2016 Q2
13 quarters
|
|
2
Chipotle Mexican Grill
CMG
$45.4B
| $1.61B | 1.36% |
95,722,100
+6,147,150
| +7% | +$98M |
2016 Q4
11 quarters
|
|
3
VeriSign
VRSN
$27.5B
| $1.56B | 1.32% |
8,282,576
+594,300
| +8% | +$122M |
2013 Q2
25 quarters
|
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $1.54B | 1.31% |
15,546,716
+6,610,931
| +74% | +$628M |
2016 Q2
13 quarters
|
|
5
Novo Nordisk
NVO
$183B
| $1.28B | 1.08% |
49,573,432
+4,529,600
| +10% | +$115M |
2013 Q2
25 quarters
|
|
6
Palo Alto Networks
PANW
$272B
| $1.19B | 1.01% |
35,088,900
+4,642,800
| +15% | +$164M |
2015 Q2
17 quarters
|
|
|
7
Biogen
BIIB
$38.2B
| $983M | 0.83% |
4,221,206
+1,738,129
| +70% | +$405M |
2018 Q1
6 quarters
|
|
8
Vertex Pharmaceuticals
VRTX
$140B
| $982M | 0.83% |
5,799,117
+243,300
| +4% | +$43M |
2017 Q1
10 quarters
|
|
9
Gilead Sciences
GILD
$210B
| $934M | 0.79% |
14,734,258
+1,994,010
| +16% | +$130M |
2014 Q4
19 quarters
|
|
10
Meta Platforms (Facebook)
META
$1.65T
| $880M | 0.74% |
4,940,233
+1,516,372
| +44% | +$288M |
2018 Q2
5 quarters
|
|
|
11
Walmart Inc
WMT
$994B
| $868M | 0.73% |
21,938,211
+7,977,165
| +57% | +$301M |
2018 Q4
3 quarters
|
|
12
Johnson & Johnson
JNJ
$680B
| $796M | 0.67% |
6,150,250
+1,809,088
| +42% | +$238M |
2015 Q3
16 quarters
|
|
13
Starbucks
SBUX
$125B
| $784M | 0.66% |
8,868,686
-534,316
| -6% | -$49.5M |
2018 Q4
3 quarters
|
|
14
Humana
HUM
$52B
| $756M | 0.64% |
2,956,318
+16,218
| +0.6% | +$4.55M |
2015 Q2
17 quarters
|
|
15
GSK
GSK
$103B
| $749M | 0.63% |
14,041,359
+1,831,934
| +15% | +$94.2M |
2013 Q2
25 quarters
|
|
16
Hershey
HSY
$34.8B
| $748M | 0.63% |
4,828,915
+588,351
| +14% | +$88.9M |
2013 Q2
25 quarters
|
|
17
Amgen
AMGN
$251B
| $708M | 0.6% |
3,658,086
+694,848
| +23% | +$133M |
2013 Q2
25 quarters
|
|
18
Duke Energy
DUK
$101B
| $704M | 0.6% |
7,344,379
-1,074,950
| -13% | -$97.8M |
2014 Q1
22 quarters
|
|
19
Atlassian
TEAM
$38.7B
| $684M | 0.58% |
5,451,799
+844,199
| +18% | +$115M |
2016 Q2
13 quarters
|
|
20
BP
BP
$114B
| $676M | 0.57% |
17,798,662
+5,313,818
| +43% | +$203M |
2017 Q2
9 quarters
|
|
21
Petrobras
PBR
$118B
| $628M | 0.53% |
43,425,400
+3,174,400
| +8% | +$46.6M |
2016 Q2
13 quarters
|
|
|
AGN
22
DELISTED
Allergan plc
AGN
| $618M | 0.52% |
3,674,168
+930,202
| +34% | +$152M |
2017 Q1
10 quarters
|
|
23
Vodafone
VOD
$36.3B
| $584M | 0.49% |
29,323,217
+5,682,906
| +24% | +$103M |
2015 Q3
16 quarters
|
|
24
TSMC
TSM
$2.03T
| $579M | 0.49% |
12,456,082
-1,846,070
| -13% | -$78.7M |
2018 Q1
6 quarters
|
|
25
Entergy
ETR
$53.7B
| $564M | 0.48% |
9,606,266
+968,800
| +11% | +$53M |
2014 Q3
20 quarters
|
|
Similar funds
Jim Simons's Q3 2019 Portfolio in Review
As of Q3 2019, Jim Simons held 3,920 positions worth $118B, up 4% from $114B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons deployed $5.29B of net new capital in Q3 2019, opening 407 new positions and adding to 1,847 existing holdings. Its largest new stake was UnitedHealth: 1,624,826 shares worth $353M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $451M trimmed.
- Jim Simons's largest Q3 2019 buy was UnitedHealth: 1,624,826 shares worth $353M.
- Jim Simons added most to Celgene Corp in Q3 2019, an estimated $628M increase.
- Jim Simons's biggest Q3 2019 reduction was Apple, cutting an estimated $451M.
- Jim Simons fully exited Red Hat Inc in Q3 2019, selling an estimated $248M.
- Jim Simons's ten largest holdings make up 11% of its $118B portfolio in Q3 2019.
- Jim Simons opened 407 new positions and closed 522 in Q3 2019.
- Jim Simons's portfolio value rose 4% quarter-over-quarter to $118B.
Based on Renaissance Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.